Connect with us


Digital Pathology Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2026


The Global Digital Pathology Market is likely to expand due to the rising use of advanced diagnostic tools for prompt diagnosis of chronic diseases. According to a report, titled “Digital Pathology: Global Market Analysis, Insights and Forecast, 2018-2025,” the market is likely to grow due to the increasing number of people diagnosed with related diseases.

Browse Complete Report Details @

The Global Digital Pathology Market is likely to grow in the forthcoming years due to recent technological advancements in pathology devices. Recent advancements have induced increasing operational efficacy, which is a major factor propelling growth in the global digital pathology market

Digital pathology is applicable across diverse domains within the healthcare industry. This, as per Fortune Business Insights, is a chief driver of the global market. Digital pathology involves producing a clear predictive image using various imaging devices. Moreover, these images can be shared or transferred through digital slides.

A hospital, research laboratory and any related center can transfer the image anywhere in the world within no time. This significantly reduces the time to treat and diagnose and eliminates the need to call upon a specialist for a consultation. The aforementioned factors have created an increasing adoption of digital pathology over other methods.

Use of Digital Pathology in Surgical Procedures Has Proven Hugely Beneficial

In surgical pathology, the diagnosed tissue can be detected, diagnosed, treated, and then incised into paper thin slices. These slices are then mounted upon glass slides, which are then examined by pathologists under microscopic conditions. This method was a first of its kind and possesses very high efficiency, besides offering clear and sharp images.

Furthermore, digital slides can be reproduced as many times as needed. Therefore, the use of pathology in surgical procedures ensures higher surgical efficiency and reduces the time required for diagnosis and operation. This has led to rapid adoption of digital pathology around the world.

Sample PDF Brochure @

Some of the Main Key Players Covered in the Report

  • 3DHISTECH – The Digital Pathology Company
  • Mikroscan Technologies, Inc.
  • Objective Pathology Services
  • Hamamatsu Photonics
  • Roche Diagnostics Danmark
  • Primera Technology
  • Biogenuix Medsystems Pvt Ltd
  • Indica Labs
  • Philips Benelux
  • Inspirata
  • LigoLab LLC
  • Leica Biosystem
  • Olympus Corporation of the Americas
  • Nikon Optical Canada Inc.

FDA Clearance for Philips’ Intellisite Pathology to Bode Well for Digital Pathology Market

In April 2017, the FDA gave its approval to Philips’ Intellisite Pathology (PIPS) for manufacturing and sale in the U.S. This was the first ever digital pathology system in the market with FDA clearance. According to Fortune Business Insights, approval to Philips’ Intellisite will encourage other pathology device manufacturers to come up with their own patents and use PIPS as a reference.

Secondly, pathologists and related clinical centers that had held off buying any type of pathology systems, until they would receive clearance from a regulatory authority, would now willingly invest and buy Philips’ Intellisite due to the FDA approval. Such factors will lead to the entry of newer market players and also encourage existing companies to improvise as well as improve their product to shake off competition from Philips.

Some of the major companies that are likely to contribute to the growth of the global digital pathology market are Digipath Inc., Hamamatsu Photonics K.K., Danaher Corporation ,Koninklijke Philips N.V., Indica Labs, Inc., Nikon Corporation, Glencoe Software, Inc., PerkinElmer, Inc., Pixcelldata Ltd., and Visiopharm A/S., Leica Biosystems, 3DHISTECH, HCL Technologies, Ventana Medical Systems,Pathology Devices, Inc., OptraSCAN, Biogenous, Spectral and Mathcore.

More Trending Topics from Future Business Insights:

Global X-ray Flat Panel Detectors Market to Value US$ 2805.2 Mn by 2025, says Fortune Business Insights

Thrombin Market 2019 Top 20 Key Players, Size Estimation, Industry Share, Business Analysis Growth Forecast to 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us

Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.

US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]


Azura Ophthalmics raises $28m for registration studies for treatment of leading cause of dry eye disease


— Medical Research Commercialisation Fund (MRCF) in raise for registration study to treat Meibomian gland dysfunction, the leading cause of Dry Eye Disease

— Meibomian gland dysfunction affects more than 30 million adults in the United States alone – registration studies used to seek potential regulatory approval with the FDA

— Financing also will support development of pipeline of new chemical entities in pre-clinical through Phase 2 development for other significant ocular surface conditions

MELBOURNE, Australia and TEL AVIV, Israel, Oct. 23, 2020 /PRNewswire/ — Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced a US$28m raise. The round included participation from existing investors, including, Brandon Capital’s Medical Research Commercialisation Fund (MRCF), OrbiMed, TPG Biotech, and Ganot Capital.

On the back of encouraging Phase 2 data, proceeds from the funding round will be used to advance Azura’s lead product candidate AZR-MD-001 into a registration study for the treatment of MGD – an eye condition where the Meibomian glands become dysfunctional, resulting in rapid evaporation of the tear film.

Registration studies are the final stage before potential Food and Drug (FDA) regulatory approval. The first study will be carried out at 14 sites across Australia and New Zealand in the first quarter of next year.

Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the build-up and shedding of the proteins at the opening of the Meibomian gland or within the gland itself – known to be the root cause of obstructive MGD. This approach has been used safely and effectively for decades in dermatology and is based on the understanding that Meibomian glands share strong similarities with sebaceous glands, skin glands responsible for conditions like acne, including the ability to undergo keratinization.

Meibomian gland dysfunction is the leading cause of evaporative Dry Eye Disease, a condition known to affect more than 30 million adults in the United States alone presenting a huge unmet need globally.[1],[2]

"The current options we have to treat patients with Meibomian gland dysfunction focus primarily on relieving obstruction and have not focused on the role of keratin within meibum. There are millions of patients with ocular surface disease and MGD worldwide; we need better treatments to help our symptomatic patients," said Dr. Preeya K. Gupta, clinical medical director of Duke Eye Center at Page Road and associate professor of ophthalmology at Duke University Eye Center, North Carolina. "The promise of Azura’s dermatological approach lies in its ability to open the glands, increase lipid production and restore tear-layer health, as well as preventing disease progression in patients with Meibomian gland dysfunction."

Azura’s lead compound AZR-MD-001 is a topical ointment applied to the lower lid that has shown a positive safety and effectiveness profile in several early-stage studies in MGD. Based on these data and interactions with the U.S. Food and Drug Administration (FDA), the company will use the funds from the financing to advance AZR-MD-001 into a registration study and seek potential regulatory approval.

"We are thrilled to enter 2021 with the additional funding that will allow us to conduct the registration studies needed to build a strong body of clinical evidence for our approach, so we can seek FDA approval for the first ophthalmic keratolytics for the treatment of Meibomian gland dysfunction," said Marc Gleeson, Sydney-based CEO of Azura. "We are grateful for the support of our investors who share our conviction that Azura’s medicines in development have the potential to transform treatment and provide hope to millions of patients suffering from unresolved eye conditions."

"On the back of positive Phase 2 data in patients with MGD, the investor syndicate are delighted to be providing this additional funding to support the progression of Azura’s lead asset into a registration clinical study," said Dr Chris Nave, CEO of the MRCF and Managing Director of Brandon Capital "In addition to its lead candidate AZR-MD-001, the company has a strong pipeline and we have great confidence in the management team’s ability to progress these promising products into clinical development and ultimately commercialization."

"The investor syndicate is committed to continuing to support the advancement of Azura’s innovative pipeline as they create medicines to target Meibomian gland dysfunction and related conditions that impact the ocular health of millions of people around the world."

About Meibomian Gland Dysfunction

Meibomian gland dysfunction (MGD) is the leading cause of Dry Eye Disease (DED), a condition known to affect more than 30 million adults in the United States alone.[1],[2] MGD is a chronic, diffuse abnormality of the Meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion.[3] There are no approved prescription pharmaceutical agents that specifically treat these glandular changes.  If left untreated, MGD will alter the tear film, resulting in damage to the front of the eye and severe discomfort from associated ocular surface diseases. Though there are treatments on the market for ocular surface diseases, many patients still suffer from dry eye, and research shows that hyperkeratinization of the Meibomian glands is the underlying cause of the disease.[4] There are currently no approved medicines for MGD.

About AZR-MD-001

Azura Ophthalmics has a robust clinical development pipeline investigating the reformulated, prescription-strength SeS2. The company has a pipeline of new chemical entities in pre-clinical through Phase 2 development for a number of ocular and lid margin diseases, including Meibomian gland dysfunction, acute use for Meibomian gland dysfunction, Inflammatory/Aqueous Deficient Dry Eye, Blepharitis, Contact Lens Discomfort and ocular manifestations of Graft versus Host Disease (GvHD).

Azura’s lead product candidate, AZR-MD-001, is a topical ointment that has been developed to yield properties ideal for ophthalmic use. The formulation would be applied to the lower lid margin before bedtime. Azura is currently evaluating the safety, tolerability and effectiveness of AZR-MD-001, developed for ophthalmic use, in a Phase 2 study in patients with MGD and evaporative DED.

AZR-MD-001 leverages SeS2 (Selenium Disulfide) as the active ingredient. SeS2 has a triple mechanism of action, it slows down keratin production; breaks down the bonds between abnormal keratin proteins; and increases the quantity of lipid produced by the Meibomian glands. If approved, AZR-MD-001 will be a first-in-class ophthalmic keratolytic for the treatment of lid margin diseases, starting with Meibomian gland dysfunction and Contact Lens Discomfort.

About Azura Ophthalmics, Ltd.

Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the US. The company is developing an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. For more information visit: and follow Azura on LinkedIn.

About the Medical Research Commercialisation Fund (MRCF) and Brandon Capital Partners

Brandon Capital Partners is a venture capital firm that manages the Medical Research Commercialisation Fund (MRCF), Australia and New Zealand’s largest life science investment fund. The MRCF is a unique collaboration between major Australian superannuation funds, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals. The MRCF supports the development and commercialisation of early-stage biomedical discoveries originating from member research organisations, providing both capital and expertise to guide the successful development of new therapies. The MRCF has supported more than 45 start-up companies to date, most of which were founded by the MRCF.

For more information about the MRCF visit:

For more information about Brandon Capital Partners visit:

[1] Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157(4):799–806.

[2] U.S. Census

[3] Nichols et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary IOVS, Special Issue 2011, Vol. 52, No. 4

[4] Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1938-78.


Related Links :

Continue Reading


Outset Medical to Report Third Quarter 2020 Financial Results on Wednesday, November 11, 2020


Outset Medical, Inc. (Nasdaq: OM) (Outset), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 11, 2020.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Rebecca Chambers, Chief Financial Officer, will host a conference call to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Wednesday, November 11, 2020. Interested parties may access the live teleconference by dialing (833) 614-1409 for domestic callers or (914) 987-7130 for international callers, followed by conference ID: 1960049. A live and archived webcast of the event will be available on the Investors section of the Outset website at

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care.

Lynn Lewis or Brian Johnston

Gilmartin Group

[email protected]

Continue Reading


Sproutly Amends Maturity Date of Private Debt


Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (Sproutly” or the Company) announced today that the Company and Infusion Biosciences Inc. (Infusion) have entered into agreements to extend the maturity dates of both the $1 million private loan issued by Infusion to the Company on January 28, 2020 (the January Infusion Loan) and the $855,000 private loan issued by Infusion to the Company on August 27, 2020 (collectively with the January Infusion Loan, the Infusion Loans) by six months.

The January Infusion Loan is evidenced by a secured convertible debenture which provides Infusion with the right to convert the principal and accrued interest on the January Infusion Loan into units of the Company at a conversion price of $0.07 per unit. Each such unit is comprised of one common share of the Company and one common share purchase warrant of the Company, with each such warrant convertible into one common share of the Company at an exercise price equal to $0.08 per share for a period of two years from the date of issue.

The Infusion Loans and the secured convertible debenture evidencing the January Infusion Loan were originally due to mature on October 24, 2020 and have each been extended to a maturity date of April 24, 2021.

For additional details regarding the Infusion Loans, please refer to the Companys news releases dated January 28, 2020 and August 27, 2020, each of which are available on the Companys SEDAR profile at

About Sproutly Canada, Inc.

Sproutlys core objective is to become the leading supplier of unique ingredients and customized formulations to the cannabis beverage and edibles market. Our water-soluble Infuz2O and BioNatural Oils will deliver revolutionary brands to international markets that are striving to produce differentiated consumer products. Sproutlys business focus is to execute on partnerships with local and globally established consumer brands to leverage their existing customer bases, further expand brand loyalty, assist with marketing, and support distribution networks to deliver this scientific breakthrough with speed and efficiency worldwide.

For more information on Sproutly, please visit:

Dr. Arup Sen, Chief Executive Officer and Director of Sproutly Canada, Inc.

Email: [email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News2 hours ago

Azura Ophthalmics raises $28m for registration studies for treatment of leading cause of dry eye disease

— Medical Research Commercialisation Fund (MRCF) in raise for registration study to treat Meibomian gland dysfunction, the leading cause of...

gbafNews28 gbafNews28
News2 hours ago

Outset Medical to Report Third Quarter 2020 Financial Results on Wednesday, November 11, 2020

Outset Medical, Inc. (Nasdaq: OM) (Outset), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity...

gbafNews28 gbafNews28
News2 hours ago

Sproutly Amends Maturity Date of Private Debt

Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (Sproutly” or the Company) announced today that the Company and Infusion...

gbafNews28 gbafNews28
News2 hours ago

Material Handling Equipment Telematics Market | Growth to be Influenced by Increase in Construction Activities | Technavio

The material handling equipment telematics market is expected to grow by USD 2.17 billion during 2020-2024. The report also provides...

gbafNews28 gbafNews28
News2 hours ago

Blueknight Announces Timing of Third Quarter 2020 Results and Conference Call

Blueknight Energy Partners, L.P. (Blueknight or the Partnership) (NASDAQ: BKEP and BKEPP), plans to release third quarter 2020 financial results...

gbafNews28 gbafNews28
News2 hours ago

Hamilton ETFs Announces October 2020 Distributions for HCA, HCAL

Hamilton Capital Partners Inc. (Hamilton ETFs) is pleased to announce the monthly cash distributions for its Hamilton Canadian Bank Mean...

gbafNews28 gbafNews28
News2 hours ago

APi Group Corporation Announces Successful Increase of Term Loan Facility and Confirms Date of Third Quarter 2020 Earnings Release

APi Group Corporation (the Company or APi) (NYSE: APG) announced today that it has entered into an incremental $250 million...

gbafNews28 gbafNews28
News2 hours ago

Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the...

gbafNews28 gbafNews28
News2 hours ago

CyberOptics Reports Strong Third Quarter Results

CyberOptics Corporation (Nasdaq: CYBE) today reported sales of $20.8 million for the third quarter of 2020 ended September 30, an...

gbafNews28 gbafNews28
News2 hours ago

Service Fulfillment Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024

The Service Fulfillment market will register an incremental spend of about USD 2,808 million, growing at a CAGR of 9.63%...